Ticker
AGRX

Price
0.45
Stock movement down
-0.02 (-3.85%)
Company name
Agile Thrpe
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Market cap
14.18M
Ent value
36.99M
Price/Sales
2.47
Price/Book
5.17
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-98.95%
3 year return
-78.16%
5 year return
-67.92%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

AGRX does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.47
Price to Book5.17
EV to Sales6.44

FINANCIALS

Per share

Loading...
Per share data
Current share count31.51M
EPS (TTM)-0.74
FCF per share (TTM)-0.70

Income statement

Loading...
Income statement data
Revenue (TTM)5.75M
Gross profit (TTM)-5.34M
Operating income (TTM)-70.36M
Net income (TTM)-69.53M
EPS (TTM)-0.74
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-92.90%
Operating margin (TTM)-1224.43%
Profit margin (TTM)-1210.15%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash3.74M
Net receivables6.34M
Total current assets14.35M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets29.30M
Accounts payable9.54M
Short/Current long term debt13.19M
Total current liabilities25.85M
Total liabilities26.56M
Shareholder's equity2.74M
Net tangible assets1.86M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-65.28M
Capital expenditures (TTM)324.00K
Free cash flow (TTM)-65.61M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-2535.00%
Return on Assets-237.33%
Return on Invested Capital-456.69%
Cash Return on Invested Capital-430.90%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.46
Daily high0.47
Daily low0.44
Daily Volume1.67M
All-time high515.20
1y analyst estimate100.00
Beta1.61
EPS (TTM)-0.74
Dividend per share-
Ex-div date-
Next earnings date31 Oct 2022

Downside potential

Loading...
Downside potential data
AGRXS&P500
Current price drop from All-time high-99.91%-12.18%
Highest price drop-99.91%-56.47%
Date of highest drop25 Aug 20229 Mar 2009
Avg drop from high-69.02%-11.38%
Avg time to new high90 days12 days
Max time to new high1855 days1805 days
COMPANY DETAILS
AGRX (Agile Thrpe) company logo
Marketcap
14.18M
Marketcap category
Small-cap
Description
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Employees
30
Investor relations
-
SEC filings
CEO
Alfred F. Altomari
Country
USA
City
Princeton
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
PRINCETON, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice Pres...
September 6, 2022
Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook and financing prospect...
August 12, 2022
Second Consecutive Quarter of Increase in Twirla Demand and Decrease in Company Operating Expenses Cash on Hand Expected to Fund Operations Through 2022 Company Announces Twirla® Product Supply Agreem...
August 11, 2022
Live Conference Call and Webcast at 4:30 p.m. ETPRINCETON, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report...
July 28, 2022
Maxim Group upgraded Agile Therapeutics Inc (NASDAQ: AGRX) to Buy from Hold with a price target of $1, saying it should be better positioned to begin to rebound. Agile recently closed an equity offeri...
July 26, 2022
In this article, we discuss the 10 best penny stocks to buy in July. If you want to see only the absolute top penny stocks to buy this month, check out 5 Best Penny Stocks to Buy in July. Penny stocks...
July 14, 2022
Agile Therapeutics Inc's (NASDAQ: AGRX) Twirla, the only low-dose transdermal hormonal contraceptive, should have tailwinds protected after the Supreme Court overturned Roe vs. Wade ruling that legali...
July 12, 2022
Agile Therapeutics Inc (NASDAQ: AGRX) expects Q2 FY22 Twirla demand to be at the mid-point of the earlier provided outlook of 20,000 - 22,000 cycles (new range 21,000 - 21,500 cycles). It represents a...
July 12, 2022
Twirla® Demand Guidance (Total Cycles) Expected to be at Midpoint of Guided Range Operating Expenses (OPEX) Expected to be Below Guided Range PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Agile T...
July 12, 2022
PRINCETON, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in a v...
July 8, 2022
Next page